RP-1828 IMMUcan

PROJECT DESCRIPTION

IMMUcan – EORTC Research Project 1828- aims to generate broad molecular (WES and RNAseq) and cellular profiling data(multiplex IF and IMC) to better understand the tumor and its microenvironment, and the impact of current therapeutic interventions.

The project will recruit 3000 patients with head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), and Breast cancers (BC) via SPECTA, as well as thanks to collaborations with ongoing European external clinical trials for access to samples of utmost interest for the project.

For each patient enrolled, a free molecular report is generated within 6 weeks, containing the clinically relevant molecular alterations.

Immucan Website

The IMMUcan consortium is an IMI initiative regrouping 26 academic and pharma partners: EORTC, Merck, SIB, EPF, IBBL, Bayer, CHUV, Katholieke Universiteit Leuven, Institut Curie, la ligue contre le cancer, Centre Léon Bérard, University of Zürich, Institut Jules Bordet, King’s College London, University of Birmingham, de Duve Institut, Charité, CRG, Owkin, Weizmann, Inserm, Abbvie, Lilly, gsk, Janssen, Sanofi, Pierre Fabre, Servier(see more).

Several expert laboratories are involved in IMMUcan. The ones responsible for the broad profiling (analysis performed on all samples) are CeGaT (Tubingen, Germany), the Bodenmiller’s lab (Zurich, Switzerland), the CHUV (Lausanne, Switzerland) and CNAG.

For all patients enrolled in the project, a molecular report containing the clinically relevant molecular alterations will be shared with the treating clinician.

Patients with non-small cell lung cancer, head and neck  squamous cell carcinoma, breast cancer, renal cell carcinoma and colorectal cancer can be eligible for this project.

List of cohort

At enrollment:

FFPE Tissue: At least one FFPE block or a minimum 15 FFPE slides

Blood:1 serum tube, 3 ACD tubes, 1 BCT, 1 PAXgene RNA tube, 1 PAXgene DNA tube, 1 EDTA tube

At progression (please check for cohort-dependent specificities):

FFPE Tissue: At least one FFPE block or a minimum 15 FFPE slides (when possible, depending on tissue availability)

Blood: 1 serum tube, 3 ACD tubes, 1 BCT, 1 PAXgene RNA tube, 1 EDTA tube

Please visit the IMMUcan website for more information.

The IMMUcan project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821558. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA. Please visit the Immucan website for more information or contact the project team 1828@eortc.org.

LIST OF COHORTS

For SPECTA, please enroll patients with the tumor type specified in the table, ONLY when the status is green. You can enroll those patients by clicking on the , next to the green status.
Study specific information (HBM, Project Specific selection criteria, CRF completion guidelines…) can be found here . Please note that your electronic database ORTA password is required for access (protocol 1553).

For any questions, please contact the project address: 1828@eortc.org.

To view the List of Cohorts, please flip your mobile phone horizontally:

Primary disease Status
Cohort 1

  • Patients with confirmed advanced or metastatic NSCLC (stage 3b and 4)
  • Naïve of any anti-local or systemic cancer treatment (in the adjuvant or metastatic settings)
Open
Primary disease Status
Cohort 1

  • Patients with confirmed locally recurrent and/or metastatic HNSCC
  • To be treated in 1st line with focus on ICI/ICI-chemo (once approved in Europe)
  • Or patient resistant to platinum, to be treated with ICI/ICI-chemo in 2nd line
Open
Cohort 2

  • Patients with confirmed progression less than 1 year after treatment with chemo-radiation, radiation only, bioradiation (of note, patients with prior surgery(ies) are also eligible)
Open
Primary disease Status
Cohort 1

  • Patients with confirmed metastatic TNBC
  • Naïve of any anti-local or systemic cancer treatment (in the adjuvant or metastatic settings)
  • To be treated in 1st line with focus on ICI/ICI-chemo
Open
Cohort 2

  • Patients with confirmed diagnostic of localized TNBC (stage I to III) breast cancer
  • To be treated with anthracycline-taxane-based neo-adjuvant therapy
  • Enrolled prior to neo-adjuvant chemotherapy
Open
Cohort 3

  • Patients with confirmed diagnostic of localized HER2+ (stage I to III) breast cancer
  • To be treated with anthracycline-taxane-based neo-adjuvant therapy
  • Enrolled prior to neo-adjuvant chemotherapy
Open
Primary disease Status
Cohort 1

  • Patients with a confirmed diagnostic of metastatic colorectal adenocarcinoma, with planned resection (curative intent) of the primary tumor and metastasis (liver and/or lung and/or peritoneal) in 1 or several successive surgical procedures and patients with metachronous metastatic disease are included as long as the resection specimen of the primary tumour is available (FFPE)
Open
Cohort 2

  • Patients with a diagnosis of widespread metastatic colorectal cancer not suitable for upfront surgery, with primary tumor tissue available from previous resection in early or palliative setting, with planned biopsy/resection of a metastatic lesion
Open
Primary disease Status
Cohort 1

  • Patients with confirmed metastatic RCC
  • To be treated in 1st line
Open
BACK TO PROJECTS